SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     




J Nucl Med. 2008; 49 (Supplement 1):286P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Nabulsi, N.
Right arrow Articles by Huang, Y.
PubMed
Right arrow Articles by Nabulsi, N.
Right arrow Articles by Huang, Y.

Radiopharmaceutical Chemistry: New Chemistry-Neurosciences

New Chemistry-Neurosciences Posters

Evaluation of the putative dopamine D3 PET tracer [11C]WC-10 in non-human primates

Nabeel Nabulsi1, David Weinzimmer1, Gabriella Gentile2, Marc Laruelle2, Zhude Tu3, Robert Mach3, Yu-Shin Ding1, Richard Carson1 and Yiyun Huang1

1 Diagnostic Radiology, Yale School of Medicine, New Haven, Connecticut; 2 GlaxoSmithKline Imaging Center & Imperial College, London, United Kingdom; 3 Washington University, St. Louis, Missouri

1220

Objectives: [11C]WC-10, a dopamine D3 antagonist with high binding affinity in vitro, has been reported to be a putative imaging agent for the D3 receptor (Mach et al: JNM 2006, 47:27p). We evaluated this tracer in non-human primates to assess its ability to image D3 receptors in vivo.

Methods: Radiolabeling was performed with [11C]methyl iodide on the AutoLoop module. PET scans were conducted on the HRRT in Rhesus monkeys. Two 120 min dynamic scans were acquired for each monkey: one control scan followed by a blocking scan with the selective D3 antagonist SB-277011. The same scan protocol was then repeated with [11C]PHNO, a D3-preferring tracer.

Results: [11C]WC-10 was prepared in 132 ± 32 mCi yield (beam condition: 55µA, 32 ± 6 min) at end of synthesis (n = 7). Radiochemical and chemical purities were ≥98%, with specific activity of 4.4 ± 1.1 Ci/µmol at the time of injection. In the control scans, heterogeneous distribution of activity was observed in the monkey brain, with the highest uptake in the cingulate cortex, followed by putamen, caudate (CD), thalamus (TH), frontal cortex, and globus pallidus (GP), and lowest uptake in the occipital cortex and cerebellum. Regional binding potential (BP) values from equilibrium data were < 0.4. With SB-277011, no reduction of BP was seen in any of the D3-rich brain regions. In contrast, when the monkeys were treated with SB-277011 and scanned with [11C]PHNO, BP were reduced by 25, 45, and 66% in the CD, GP, and TH, respectively.

Conclusions: Evaluation of [11C]WC-10 in vivo indicated that it does not possess the right properties as a PET tracer for imaging the dopamine D3 receptor in the monkey brain.

Research Support: GSK





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Nabulsi, N.
Right arrow Articles by Huang, Y.
PubMed
Right arrow Articles by Nabulsi, N.
Right arrow Articles by Huang, Y.